VPC-70063

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

VPC-70063 是 c-Myc-MAX 的抑制剂。 VPC-70063 对 Myc-Max 转录活性抑制为 106%，IC50 为 8.9 μM，对 Myc-Max/UBE2C 下游通路抑制为 94%。 VPC-70063可用于抗癌研究。

VPC-70063 is an inhibitor of c-Myc-MAX. VPC-70063 exhibits Myc-Max transcriptional activity inhibition of 106% with an IC50 of 8.9 μM and Myc-Max/UBE2C downstream pathway inhibition of 94%. VPC-70063 can be used for studies about anticancer.(In Vitro):VPC-70063 (6.25, 12.5, and 25 μM) causes apoptosis of LNCaP cells as indicated by cleavage of PARP. VPC-70063 (0-500 μM) disrupts the interaction of Myc-Max with DNA in a dose-dependent manner.

VPC-70063 (25 μM; 96 h) shows Myc-Max transcriptional activity inhibition of 106% and Myc-Max/UBE2C downstream pathway inhibition of 94%.VPC-70063 (6.25-25 μM, 48 h) causes apoptosis of LNCaP cells as indicated by cleavage of PARP.VPC-70063 (0-500 μM; 0-600 s) disrupts the interaction of Myc-Max with DNA in a dose dependent manner.Western Blot Analysis Cell Line:LNCaP cells Concentration:6.25 μM, 12.5 μM and 25 μM Incubation Time:48 h Result:Induced PARP cleavage.

——

Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(phenylmethyl)-

Apoptosis

Apoptosis

P2X3

——

——

13571-44-3

378.33

C16H12F6N2S

>98% (HPLC)

——

FC(F)(F)C1=CC(=CC(=C1)C(F)(F)F)NC(=S)NCC=2C=CC=CC2

——

(-20℃)

With Ice Pack

≥ 2 years